Menu
GWAS Study

Genome-wide association study of Alzheimer's disease.

Kamboh MI, Demirci FY, Wang X et al.

22832961 PubMed ID
GWAS Study Type
8292 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

KM
Kamboh MI
DF
Demirci FY
WX
Wang X
MR
Minster RL
CM
Carrasquillo MM
PV
Pankratz VS
YS
Younkin SG
SA
Saykin AJ
JG
Jun G
BC
Baldwin C
LM
Logue MW
BJ
Buros J
FL
Farrer L
PM
Pericak-Vance MA
HJ
Haines JL
SR
Sweet RA
GM
Ganguli M
FE
Feingold E
DS
Dekosky ST
LO
Lopez OL
BM
Barmada MM
Chapter II

Abstract

Summary of the research findings

In addition to apolipoprotein E (APOE), recent large genome-wide association studies (GWASs) have identified nine other genes/loci (CR1, BIN1, CLU, PICALM, MS4A4/MS4A6E, CD2AP, CD33, EPHA1 and ABCA7) for late-onset Alzheimer's disease (LOAD). However, the genetic effect attributable to known loci is about 50%, indicating that additional risk genes for LOAD remain to be identified. In this study, we have used a new GWAS data set from the University of Pittsburgh (1291 cases and 938 controls) to examine in detail the recently implicated nine new regions with Alzheimer's disease (AD) risk, and also performed a meta-analysis utilizing the top 1% GWAS single-nucleotide polymorphisms (SNPs) with P<0.01 along with four independent data sets (2727 cases and 3336 controls) for these SNPs in an effort to identify new AD loci. The new GWAS data were generated on the Illumina Omni1-Quad chip and imputed at ~2.5 million markers. As expected, several markers in the APOE regions showed genome-wide significant associations in the Pittsburg sample. While we observed nominal significant associations (P<0.05) either within or adjacent to five genes (PICALM, BIN1, ABCA7, MS4A4/MS4A6E and EPHA1), significant signals were observed 69-180 kb outside of the remaining four genes (CD33, CLU, CD2AP and CR1). Meta-analysis on the top 1% SNPs revealed a suggestive novel association in the PPP1R3B gene (top SNP rs3848140 with P = 3.05E-07). The association of this SNP with AD risk was consistent in all five samples with a meta-analysis odds ratio of 2.43. This is a potential candidate gene for AD as this is expressed in the brain and is involved in lipid metabolism. These findings need to be confirmed in additional samples.

1,291 European ancestry cases, 938 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

8292
Total Participants
GWAS
Study Type
Yes
Replicated
509 European ancestry cases, 753 European ancestry controls, 2,218 cases, 2,583 controls
Replication Participants
European
Ancestry
U.S., Greece, Canada, Germany
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.